Aclaris Therapeutics, Inc. ($ACRS) reported second-quarter 2026 revenue of $1.6 million, down 8.3% from a year earlier. Gross profit rose 11.8% to $1.4 million, helped by a sharp decline in cost of sales.
Operating losses narrowed on a year-over-year basis, with operating profit at $(24.2 million) and net income attributable to common shareholders at $(21.5 million). Diluted earnings per share came in at $(0.15).
Cash flow remained negative, with operating activities using $19.8 million in the quarter. The company ended the period with $28.7 million in cash and cash equivalents, while total liabilities were $55.1 million.
- Revenue: $1.6 million
- Gross profit: $1.4 million
- Operating loss: $(24.2 million)
- Net loss: $(21.5 million)
- Cash and cash equivalents: $28.7 million
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Aclaris Therapeutics, Inc. Insider Trading Activity
Aclaris Therapeutics, Inc. insiders have traded $ACRS stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ACRS stock by insiders over the last 6 months:
- BRADEN MICHAEL LEONARD sold 300,000 shares for an estimated $1,359,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Aclaris Therapeutics, Inc. Hedge Fund Activity
We have seen 69 institutional investors add shares of Aclaris Therapeutics, Inc. stock to their portfolio, and 51 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP added 9,345,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $35,043,750
- RA CAPITAL MANAGEMENT, L.P. added 6,804,072 shares (+inf%) to their portfolio in Q1 2026, for an estimated $25,515,270
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. added 4,925,374 shares (+inf%) to their portfolio in Q1 2026, for an estimated $18,470,152
- BALYASNY ASSET MANAGEMENT L.P. added 3,361,328 shares (+inf%) to their portfolio in Q1 2026, for an estimated $12,604,980
- NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO removed 1,898,561 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $7,119,603
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,407,144 shares (-26.7%) from their portfolio in Q1 2026, for an estimated $5,276,790
- CITADEL ADVISORS LLC added 1,044,038 shares (+86.6%) to their portfolio in Q1 2026, for an estimated $3,915,142
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Aclaris Therapeutics, Inc. Analyst Ratings
Wall Street analysts have issued reports on $ACRS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- LifeSci Capital issued a "Outperform" rating on 06/02/2026
To track analyst ratings and price targets for Aclaris Therapeutics, Inc., check out Quiver Quantitative's $ACRS forecast page.
Aclaris Therapeutics, Inc. Price Targets
Multiple analysts have issued price targets for $ACRS recently. We have seen 6 analysts offer price targets for $ACRS in the last 6 months, with a median target of $11.5.
Here are some recent targets:
- An analyst from LifeSci Capital set a target price of $13.0 on 06/02/2026
- Seamus Fernandez from Guggenheim set a target price of $12.0 on 05/05/2026
- Biren Amin from Piper Sandler set a target price of $11.0 on 05/05/2026
- Martin Fan from Wedbush set a target price of $10.0 on 04/29/2026
- Jeff Jones from Oppenheimer set a target price of $10.0 on 04/16/2026
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $16.0 on 03/19/2026
